Co-radiotherapy with tyrosine kinase inhibitors might benefit survival in hepatoma patients with portal vein tumor thrombosis
Biomedical Journal · 2026-04 · 49 (2) · 100904
DOI: 10.1016/j.bj.2025.100904 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Journal, 2026-04. Verfasst von Hui-Ling Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, Chang Gung Memorial Hospital, Chiayi, Taiwan; Multidisciplinary Team for Liver Cancer, Chang Gung Memorial Hospital, Chiayi, T…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Portal Vein, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancer Center, University of Florida Health, Chiayi Chang Gung Memorial Hospital.
Abstract (Originalsprache)
BACKGROUND: Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is associated with a poor prognosis, and current treatment options yield suboptimal results. This article aims to share our treatment outcomes for PVTT using tyrosine kinase inhibitors (TKIs), radiation therapy (RT), and their combination. METHODS: From 2010 to 2021, a total of 160 Child-Pugh class A HCC patients with PVTT, but without extrahepatic spread, were enrolled. Among them, 26, 10, 81, and 43 patients underwent no treatment, RT, TKIs, and combination therapy, respectively. RESULTS: Compared to the no treatment group (median survival: 2 months), the RT group (4.5 months, p = 0.034), TKIs group (5.0 months, p = 0.0017), and combination group (15.0 months, p < 0.001) all demonstrated a survival benefit. The multivariate Cox model showed adjusted hazard ratios and 95 % confidence intervals of 0.35 (0.16-0.78), 0.40 (0.25-0.63) and 0.26 (0.15-0.44) for RT, TKIs, combination groups, respectively. From clinical observation of patients who survived for two years, we found that 20 % of RT patients achieved good local control, and the RT group had longer durations of TKI use. CONCLUSIONS: In this series, 26.9 % (43/160) of HCC patients with PVTT underwent combination treatment with TKIs and RT, achieving a median survival of 15.0 months. The contributions of RT were 20 % disease control rate and may extend the duration of TKIs use. Therefore, all candidates without contraindications should be considered for combination treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nursing, Chang Gung Memorial Hospital, Chiayi, Taiwan; Multidisciplinary Team for Liver Cancer, Chang Gung Memorial Hospital, Chiayi, Taiwan.
- Department of Diagnostic Radiology, Chang Gung Memorial Hospital, Chiayi, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan; Multidisciplinary Team for Liver Cancer, Chang Gung Memorial Hospital, Chiay…
- Department of Radiation Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan; Multidisciplinary Team for Liver Cancer, Chang Gung Memorial Hospital, Chiayi, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan, Taiwan; Department of Hepatology and Gastroenterology, Division of Internal Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan; Multidisciplinary Team for Liver C…
- Department of Hepatology and Gastroenterology, Division of Internal Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan; Department of Hepato-Gastroenterology, Division of Internal Medicine, Kaohsiung Chang Gung Memo…
Förderung
- Cancer Center, University of Florida Health
- Chiayi Chang Gung Memorial Hospital
Zitieren
APA
Huang, H. L., Lin, W. M., Lai, C. H., Chang, T. S., & Lu, S. N. (2026). Co-radiotherapy with tyrosine kinase inhibitors might benefit survival in hepatoma patients with portal vein tumor thrombosis. Biomedical Journal, 49(2), 100904. https://doi.org/10.1016/j.bj.2025.100904
Vancouver
Huang HL, Lin WM, Lai CH, Chang TS, Lu SN. Co-radiotherapy with tyrosine kinase inhibitors might benefit survival in hepatoma patients with portal vein tumor thrombosis. Biomedical Journal. 2026;49(2):100904. doi:10.1016/j.bj.2025.100904
BibTeX
@article{Huang2026,
author = {Huang, Hui-Ling and Lin, Wei-Ming and Lai, Chia-Hsuan and Chang, Te-Sheng and Lu, Sheng-Nan},
title = {Co-radiotherapy with tyrosine kinase inhibitors might benefit survival in hepatoma patients with portal vein tumor thrombosis},
journal = {Biomedical Journal},
year = {2026},
volume = {49},
number = {2},
pages = {100904},
doi = {10.1016/j.bj.2025.100904}
}
EUVIMED